- Home
- MUA vs CCCC Comparison
MUA vs CCCC Comparison
Compare MUA & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUA
- CCCC
- Stock Information
- Founded
- MUA 1993
- CCCC 2015
- Country
- MUA United States
- CCCC United States
- Employees
- MUA N/A
- CCCC N/A
- Industry
- MUA Investment Bankers/Brokers/Service
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- MUA Finance
- CCCC Health Care
- Exchange
- MUA Nasdaq
- CCCC Nasdaq
- Market Cap
- MUA 474.4M
- CCCC 396.0M
- IPO Year
- MUA N/A
- CCCC 2020
- Fundamental
- Price
- MUA $10.99
- CCCC $3.93
- Analyst Decision
- MUA
- CCCC Buy
- Analyst Count
- MUA 0
- CCCC 6
- Target Price
- MUA N/A
- CCCC $10.67
- AVG Volume (30 Days)
- MUA 92.6K
- CCCC 1.9M
- Earning Date
- MUA 01-01-0001
- CCCC 02-20-2025
- Dividend Yield
- MUA 4.84%
- CCCC N/A
- EPS Growth
- MUA N/A
- CCCC N/A
- EPS
- MUA N/A
- CCCC N/A
- Revenue
- MUA N/A
- CCCC $33,668,000.00
- Revenue This Year
- MUA N/A
- CCCC $75.79
- Revenue Next Year
- MUA N/A
- CCCC N/A
- P/E Ratio
- MUA N/A
- CCCC N/A
- Revenue Growth
- MUA N/A
- CCCC 65.45
- 52 Week Low
- MUA $8.61
- CCCC $3.61
- 52 Week High
- MUA $11.43
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- MUA 26.53
- CCCC 41.31
- Support Level
- MUA $10.82
- CCCC $3.73
- Resistance Level
- MUA $11.15
- CCCC $4.21
- Average True Range (ATR)
- MUA 0.17
- CCCC 0.45
- MACD
- MUA -0.07
- CCCC 0.02
- Stochastic Oscillator
- MUA 15.74
- CCCC 18.12
About MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.